We are live on ! Find out more

Drug Manufacturers - General
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
IBO
26
Impact BioMedical
IBO
$51.8M
$51.8M $0.4800 6.83%
NSRX
27
Nasus Pharma
NSRX
$46.8M
$46.8M $4 3.9%
XTNT icon
28
Xtant Medical Holdings
XTNT
$45.6M
$45.6M $0.3249 2.52%
CPHI icon
29
China Pharma Holdings
CPHI
$42.2M
$42.2M $0.9800 7.55%
SCLX icon
30
Scilex Holding
SCLX
$40.3M
$40.3M $5.73 1.21%
ATNM icon
31
Actinium Pharmaceuticals
ATNM
$34.5M
$34.5M $1.10 1.79%
NNVC icon
32
NanoViricides
NNVC
$33.9M
$33.9M $1.33 1.53%
MIRA icon
33
MIRA Pharmaceuticals
MIRA
$32.1M
$32.1M $0.7636 7.53%
IGC icon
34
IGC Pharma
IGC
$31.8M
$31.8M $0.3080 11.1%
CVM icon
35
CEL-SCI Corp
CVM
$25M
$25M $1.42 2.74%
MDCX
36
Medicus Pharma
MDCX
$17.2M
$17.2M $0.2718 0.15%
RGNT
37
Regentis Biomaterials
RGNT
$14.8M
$14.8M $2.10 1.94%
TOVX icon
38
Theriva Biologics
TOVX
$10.8M
$10.8M $0.2350 2.09%
AEON icon
39
AEON Biopharma
AEON
$9.58M
$9.58M $0.1921 0.52%
AZTR icon
40
Azitra
AZTR
$8.05M
$8.05M $0.1328 4.81%
AIM
41
AIM ImmunoTech
AIM
$7.87M
$7.87M $0.2584 2.09%
APUS
42
Apimeds Pharmaceuticals US
APUS
$7.3M
$7.3M $4.84 10.3%
CANF
43
Can-Fite BioPharma American Depositary Shares
CANF
$7.13M
$7.13M $3.33 0.6%
KAPA
44
Kairos Pharma
KAPA
$6.87M
$6.87M $0.2900 1.73%
PHGE icon
45
BiomX
PHGE
$3.65M
$3.65M $0.1375 1.57%
CLDI icon
46
Calidi Biotherapeutics
CLDI
$3.46M
$3.46M $1.34 0%
MTNB icon
47
Matinas BioPharma
MTNB
$2.92M
$2.92M $0.1988 8.93%
OGEN icon
48
Oragenics
OGEN
$2.37M
$2.37M $0.5250 2.78%
1
2

Drug Manufacturers - General Stocks at a Glance

Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.

There are 48 Drug Manufacturers - General industry stocks tracked by Wall St. Rank, worth a combined $4.35T.

The largest by market cap are Eli Lilly (LLY) at $1.12T, Johnson & Johnson (JNJ) at $651B and AbbVie (ABBV) at $468B.

Among institutional investors, Eli Lilly (LLY) drew the most net new fund positions in Q2 2026: 411 funds opened new positions, taking total fund holders up 229 (5.2%) quarter-over-quarter.

  • Combined market cap: $4.35T across 48 stocks.
  • Largest constituent: Eli Lilly (LLY), $1.12T market cap.
  • Most net new fund positions in Q2 2026: Eli Lilly (LLY), +229 holders.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.